Leishmaniases are a group of neglected tropical diseases caused by protozoan parasites of the genus Leishmania. The global incidence of these diseases is estimated to be between 700,000 and 1 million new cases per year. Given the concerns related to current antileishmanial drugs, such as parental administration and toxicity, the need for new alternative drugs is clear. In this context, arginase emerges as a potential molecular target for the discovery of novel inhibitors. Arginase is a manganese-dependent enzyme that catalyzes the production of polyamines from L-arginine, and its inhibition in Leishmania disrupts polyamine metabolism, which is essential for parasite survival and proliferation. Therefore, the present study employed a virtual screening strategy, including molecular docking, molecular dynamics (MD) simulations, and ADMET (absorption, distribution, metabolism, elimination, and toxicity) analysis, to identify potential inhibitors of Leishmania amazonensis arginase (LaARG) from an in-house chemolibrary of 66 compounds. The thiazolidinone LaSMMed47 emerged as the top hit, demonstrating strong interactions with Mn2+ ions at the catalytic site of LaARG. The structural stability of the LaSMMed47-LaARG complex was confirmed by MD simulations for 200 ns. Furthermore, ADMET predictions indicated that LaSMMed47 possesses favorable drug-likeness, high gastrointestinal absorption, and a low toxicity profile. Since LaSMMed47 is a previously unreported compound, it was synthesized in this study with a 64% yield; its structure and purity were confirmed through melting point, NMR (1H and 13C), IR, and HRMS analyses. The in vitro inhibition of bovine arginase by LaSMMed47 was evaluated by determining the percentage of inhibition (%I), which was 28.1%. Phenotypic in vitro assays also demonstrated the antileishmanial activity, with LaSMMed47 exhibiting an IC50 of 1.7 μM against promastigotes and 0.03 μM against intracellular amastigotes of L. amazonensis. Additionally, the compound demonstrated low toxicity in murine macrophages (CC50 > 100 μM), resulting in a high selectivity index for both developmental forms of the parasite. Together, these results indicate that thiazolidinones, particularly LaSMMed47, are promising chemical scaffolds for developing selective arginase inhibitors and new treatment options for leishmaniasis.